All News
Filter News
Found 296 articles
-
Arcturus Therapeutics to Participate in the SVB Leerink 11th Annual Global Healthcare Conference
2/8/2022
Arcturus Therapeutics Holdings Inc. announced that members of the Company’s management team will be participating in the SVB Leerink 11th Annual Global Healthcare Conference 2022.
-
Clinical trial news definitely picked up this final week of January. Here’s a look.
-
Arcturus Therapeutics Reports New Data Demonstrating Neutralizing Antibody Immune Response to the SARS-CoV-2 Omicron Variant from ARCT-154 and ARCT-165 Booster Clinical Trial
1/25/2022
Arcturus Therapeutics Holdings Inc. today announced new data from clinical development programs for ARCT-154 and ARCT-165, its investigational, next-generation, self-amplifying mRNA vaccine candidates targeting variants of concern.
-
Arcturus Therapeutics Updates Data from ARCT-154 and ARCT-165 Booster Clinical Trial Demonstrating Robust Neutralizing Antibody Responses to SARS-CoV-2 and Several Variants
1/24/2022
Arcturus Therapeutics Holdings Inc. today announced updated data from clinical development programs for ARCT-154 and ARCT-165.
-
Ocugen Inc. Announces Nirdosh Jagota, Ph.D. as Senior Vice President, Regulatory Affairs, Compliance & Safety
1/24/2022
Ocugen, Inc. today announced the appointment of Nirdosh Jagota, Ph.D., as Senior Vice President (SVP), Regulatory Affairs, compliance and safety.
-
Arcturus Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - Jan 22, 2022
1/22/2022
Arcturus Therapeutics Holdings Inc. announced that the Compensation Committee of the Company’s Board of Directors and the Company’s Board of Directors approved inducement grants of stock options to purchase an aggregate of 5,800 shares of Arcturus’s common stock to one newly-hired employee.
-
Krystal Biotech Appoints Jing Marantz, MD, PhD, MBA as Chief Business Officer and Rand Sutherland, MD, MPH to its Board of Directors
1/18/2022
Krystal Biotech, Inc. announced today the appointments of Jing Marantz as Chief Business Officer and Rand Sutherland as a new member of the Board of Directors.
-
Arcturus Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - Dec 18, 2021
12/18/2021
Arcturus Therapeutics Holdings Inc. announced that the Compensation Committee of the Company’s Board of Directors and the Company’s Board of Directors approved inducement grants of stock options to purchase an aggregate of 13,800 shares of Arcturus’ common stock to three newly-hired employees.
-
BioSpace Movers & Shakers, Dec. 17
12/17/2021
As 2021 moves closer to its end, biopharma and life sciences companies from across the globe continue to strengthen their leadership teams and boards with these Movers & Shakers. -
Arcturus Therapeutics Reports New Data and Provides Additional Updates from ARCT-154 and ARCT-165 Clinical Trials
12/16/2021
Arcturus Therapeutics Holdings Inc. today announced new data and updates from clinical development programs for ARCT-154 and ARCT-165.
-
Arcturus Therapeutics Appoints Jing Marantz, M.D., Ph.D., M.B.A. to its Board of Directors
12/13/2021
Arcturus Therapeutics Holdings Inc. today announced the appointment of Jing Marantz, M.D., Ph.D., M.B.A., an experienced biopharma industry executive, to its Board of Directors.
-
Ultragenyx Announces First Patient Dosed in Phase 1/2 Clinical Study of UX053, an mRNA Therapy for the Treatment of Glycogen Storage Disease Type III
12/1/2021
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), today announced that the first patient has been dosed in its Phase 1/2 study of UX053, an investigational messenger RNA (mRNA) therapy in development for the treatment of Glycogen Storage Disease Type III (GSDIII).
-
Arcturus Therapeutics to Participate in Piper Sandler 33rd Annual Healthcare Conference
11/22/2021
Arcturus Therapeutics Holdings Inc. today announced that members of the Company’s management team will be participating in the Piper Sandler’s 33rd Annual Virtual Healthcare Conference and investor meetings November 30 and December 2, 2021.
-
Arcturus Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - Nov 19, 2021
11/19/2021
Arcturus Therapeutics Holdings Inc. announced that the Compensation Committee of the Company’s Board of Directors and the Company’s Board of Directors approved inducement grants of stock options to purchase an aggregate of 185,700 shares of Arcturus’s common stock to 16 newly-hired employees, contingent upon the filing of a Form S-8 Registration Statement.
-
Arcturus Therapeutics Announces Third Quarter 2021 Financial Update and Pipeline Progress
11/8/2021
Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a leading clinical-stage messenger RNA medicines company focused on the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases, today announced its financial results for the third quarter ended September 30, 2021 and provided corporate updates.
-
Arcturus Therapeutics to Report Third Quarter 2021 Financial Results and Provide Corporate Update on November 8, 2021
10/25/2021
Arcturus Therapeutics Holdings Inc. today announced that it will release its financial results for the third quarter ended September 30, 2021 after the market close on Monday November 8,
-
BioSpace Movers & Shakers, Oct. 22
10/22/2021
Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers. -
Arcturus Therapeutics Announces Leadership Appointments
10/21/2021
Arcturus Therapeutics Holdings Inc. announced the appointments of Dr. Nirdosh Jagota as the Chief Regulatory Officer and Dr. Dushyant B. Varshney as the Chief Technology Officer.
-
Arcturus Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - Oct 21, 2021
10/21/2021
Arcturus Therapeutics Holdings Inc. announced that the Compensation Committee of the Company’s Board of Directors and the Company’s Board of Directors approved inducement grants of stock options to purchase an aggregate of 57,200 shares of Arcturus’ common stock to 5 newly-hired employees, contingent upon the filing of a Form S-8 Registration Statement.
-
Clinical Catch-Up: October 11-15
10/18/2021
It was yet another busy week for clinical trial announcements. Take a look.